UK-BASED Amicus Therapeutics has today confirmed the debut of commercial operations in Australia, along with the addition of its oral precision medicine Galafold (migalastat) on the Life Saving Drugs Program (LDSP).
Galafold is being listed on the LDSP for the long term treatment of Fabry Disease patients aged over 16 with a suitable genetic mutation.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Nov 18
